サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1768774

3Dバイオプリンティングの世界市場

3D Bioprinting

出版日
ページ情報
英文 170 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
3Dバイオプリンティングの世界市場
出版日: 2025年07月11日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 170 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

3Dバイオプリンティングの世界市場は2030年までに89億米ドルに達する見込み

2024年に37億米ドルと推定される3Dバイオプリンティングの世界市場は、2024年から2030年にかけてCAGR 15.7%で成長し、2030年には89億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるインクジェットベースは、CAGR16.3%を記録し、分析期間終了までに37億米ドルに達すると予測されます。磁気浮上式セグメントの成長率は、分析期間のCAGRで16.9％と推定されます。

米国市場は10億米ドル、中国はCAGR14.8%で成長予測

米国の3Dバイオプリンティング市場は、2024年に10億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.9%と13.0%と予測されています。欧州では、ドイツがCAGR 11.2%で成長すると予測されています。

世界の3Dバイオプリンティング市場- 主要動向と促進要因まとめ

3Dバイオプリンティングとは何か？

3Dバイオプリンティングは、3Dプリンティングの原理と生物科学を組み合わせ、機能的な組織や臓器を作り出す画期的な技術です。このプロセスでは、生きた細胞と生体適合性材料からなる物質であるバイオインクを層ごとに堆積させ、人間の組織の生物学的複雑性を再現した構造を構築します。3Dバイオプリンティングの最初のステップはデジタル設計の段階であり、そこでは組織や臓器のモデルが専用のソフトウェアを使って作成されます。このデジタル設計図によって、プリンターは極めて正確にバイオインクを配置することができます。バイオインク自体は、人間の細胞の自然環境を模倣し、その成長と開発を促進するように注意深く調合されます。印刷後、構築された組織は、細胞の成熟と組織化を可能にするために、制御された環境で培養され、時には足場材料によってサポートされます。3Dバイオプリンティングの潜在的応用範囲は、皮膚移植片や軟骨の製造から、肝臓や腎臓のようなより複雑な臓器に至るまで、広大です。バイオプリンティング技術が進化するにつれ、従来の組織工学や臓器移植法が直面していた多くの限界を克服することが期待されます。

3Dバイオプリンティングは医療とヘルスケアをどのように変革するのか？

3Dバイオプリンティングが医療とヘルスケアに与える変革的な影響は、すでに明らかになりつつあり、この技術はいくつかの重要な分野で革命的なソリューションを提供しています。最も重要な応用例のひとつは臓器移植で、バイオプリンティングは慢性的なドナー臓器不足を解決する可能性を秘めています。研究者たちは、腎臓、心臓、肺など、機能的で患者固有の臓器をプリントすることで飛躍的な進歩を遂げつつあります。プリントされた臓器はレシピエント自身の細胞から作られるため、待ち時間を大幅に短縮し、臓器拒絶反応のリスクを下げることができます。移植にとどまらず、3Dバイオプリンティングは、火傷患者用の皮膚や関節修復用の軟骨など、回復を早め、患者の予後を改善することができる個別化された組織インプラントの作成を可能にすることで、再生医療の分野を強化しています。この技術は、医薬品の試験開発にも大きな影響を及ぼしています。従来、製薬会社は前臨床試験を動物モデルに頼ってきたが、こうしたモデルは必ずしも人間の反応を正確に予測するものではないです。バイオプリントされたヒト組織は、より信頼性の高い医薬品試験のプラットフォームを提供し、潜在的な治療法のスクリーニングを改善し、医薬品開発パイプラインにおけるコストのかかる後期段階の失敗を減らすことを可能にします。技術の進歩に伴い、完全に機能する臓器や個別化された治療法を生み出す可能性はますます大きくなり、ヘルスケアの展望は大きく変わると思われます。

3Dバイオプリンティングにおける課題と倫理的配慮とは？

3Dバイオプリンティングは、その有望な応用にもかかわらず、その可能性を最大限に発揮するために対処すべきいくつかの技術的、倫理的、規制上の課題に直面しています。主な技術的ハードルのひとつは、人体内で生存し、統合できる機能的組織を印刷することの複雑さです。皮膚や軟骨のような単純な組織はバイオプリントに成功しているが、肝臓や心臓のような複雑な臓器には大きな課題があります。これらの臓器は、すべての部位への十分な血液供給を確保するために複雑な血管網を必要とし、このような複雑な構造を複製することは依然として大きな課題です。さらに、ヒト組織の多様な機械的・生物学的特性を正確に再現できるバイオインクの開発は、現在進行中の研究分野です。倫理的には、ヒト組織をプリントする能力は、多くの懸念を引き起こします。完全に機能するヒトの臓器を作る可能性は、ヒトのクローニングやヒト組織の商品化をめぐる議論につながる可能性があります。さらに、この技術は当初は法外に高価で、経済的に余裕のある人しか利用できず、ヘルスケアの不平等をさらに悪化させる可能性があるため、公平な分配についても懸念があります。規制面では、バイオプリンティングがもたらす独自の課題に、規制当局がまだ適応していないです。従来の医療機器や医薬品とは異なり、バイオプリンティングで作られた組織や臓器は、生物学的産物と合成物質の境界線をまたいでいるため、臨床現場で広く使用されるようになるまでに、その安全性と有効性をどのように確保するかという問題が生じています。これらの課題に取り組むことは、3Dバイオプリンティング技術の普及と倫理的使用にとって極めて重要です。

3Dバイオプリンティング市場成長の促進要因は？

3Dバイオプリンティング市場の成長の原動力はいくつかの要因であり、そのどれもが、この革命的なテクノロジーに対する需要が複数の産業で高まっていることを浮き彫りにしています。技術の進歩は、市場の拡大に重要な役割を果たしています。より複雑なデザインが可能な高解像度プリンターや、人体組織をよりよく模倣するバイオインク製剤の進歩など、バイオプリンティング機器の革新は、実現可能なことの限界を押し広げ続けています。こうした改良によって医療用途に新たな可能性が生まれ、官民双方からの投資が集まっています。製薬会社もまた、バイオプリンティングを利用して創薬や試験のプロセスを加速させており、成長の大きな原動力となっています。この技術は、動物実験に頼ることが多く、ヒトの生物学にうまく反映されない可能性がある従来の方法に対して、より信頼性が高く、費用対効果の高い代替手段を提供します。さらに、心臓病や肝不全など、高齢化に伴う慢性疾患や病態の増加が、再生医療ソリューションへの需要を促進しており、3Dバイオプリンティングは転帰を改善できる患者固有の治療を提供しています。もう一つの重要な要因は、個別化医療に対する消費者の嗜好の高まりです。患者やヘルスケアプロバイダーは、個々の遺伝子プロファイルに合わせた治療を求めるようになっており、バイオプリンティングは、各患者固有のニーズに合わせてカスタマイズされた組織や臓器を作り出す可能性を提供しています。最後に、政府資金の流入と学術機関との提携がこの分野の研究開発に拍車をかけ、バイオプリンティング技術の革新と商業化をさらに加速させています。これらの動向は、3Dバイオプリンティングが、臓器移植から医薬品開発まで幅広い用途を持つ、将来のヘルスケアに不可欠な存在となる準備が整っていることを示しています。

セグメント

技術（インクジェットベース、磁気浮上、レーザーベース、その他の技術）、材料（生体細胞、ハイドロゲル、細胞外マトリックス、その他の材料）、エンドユーザー（研究機関・学術機関、バイオ製薬会社、病院）

調査対象企業の例

  • 3D Bioprinting Solutions
  • 3D Systems
  • Advanced Solutions Life Sciences
  • Allevi Inc.
  • Aspect Biosystems Ltd.
  • Bio3D Technologies
  • Cellink
  • Cellink Global
  • Cyfuse Biomedical K.K.
  • Digilab, Inc.
  • Envisiontec
  • Gesim
  • Inventia Life Science Pty Ltd.
  • Materialise NV
  • Nano3D Biosciences, Inc.
  • Oceanz 3D printing & Additive Manufacturing
  • Organovo Holdings, Inc.
  • Poietis
  • Regemat 3D S.L.
  • Regenhu
  • Regenovo Biotechnology Co., Ltd.
  • Rokit Healthcare
  • Solidscape
  • Stratasys Ltd.
  • Tevido Biodevices
  • Vivax Bio, LLC
  • Voxeljet

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP21002

Global 3D Bioprinting Market to Reach US$8.9 Billion by 2030

The global market for 3D Bioprinting estimated at US$3.7 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2024-2030. Inkjet-based, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Magnetic Levitation segment is estimated at 16.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 14.8% CAGR

The 3D Bioprinting market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.9% and 13.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.2% CAGR.

Global 3D Bioprinting Market - Key Trends and Drivers Summarized

What Is 3D Bioprinting and How Does It Work?

3D bioprinting is a groundbreaking technology that combines the principles of 3D printing with biological sciences to create functional tissues and organs. The process involves the layer-by-layer deposition of bio-inks, which are substances composed of living cells and biocompatible materials, to build structures that replicate the biological complexity of human tissues. The first step in 3D bioprinting is the digital design phase, where a model of the tissue or organ is created using specialized software. This digital blueprint guides the printer in placing bio-inks with extreme precision. The bio-inks themselves are carefully formulated to mimic the natural environment of human cells, promoting their growth and development. After printing, the constructed tissue is cultivated in a controlled environment to allow for cellular maturation and organization, sometimes supported by scaffolding materials. The potential applications of 3D bioprinting are vast, ranging from the production of skin grafts and cartilage to more complex organs like the liver and kidneys. As bioprinting technology evolves, it promises to overcome many of the limitations faced by traditional tissue engineering and organ transplantation methods.

How Is 3D Bioprinting Transforming Medicine and Healthcare?

The transformative impact of 3D bioprinting on medicine and healthcare is already becoming evident, with the technology offering revolutionary solutions in several key areas. One of the most significant applications is in organ transplantation, where bioprinting holds the promise of solving the chronic shortage of donor organs. Researchers are making strides in printing functional, patient-specific organs, such as kidneys, hearts, and lungs, which could drastically reduce waiting times and lower the risk of organ rejection, as the printed organs can be made from the recipient’s own cells. Beyond transplantation, 3D bioprinting is enhancing the field of regenerative medicine by enabling the creation of personalized tissue implants, such as skin for burn victims or cartilage for joint repair, that can accelerate recovery and improve patient outcomes. This technology is also having a profound effect on drug testing and development. Traditionally, pharmaceutical companies have relied on animal models for preclinical testing, but these models do not always accurately predict human responses. Bioprinted human tissues offer a more reliable platform for drug testing, allowing for better screening of potential treatments and a reduction in costly late-stage failures in drug development pipelines. As the technology advances, the potential for creating fully functional organs and personalized medical treatments will continue to grow, reshaping the healthcare landscape.

What Are the Challenges and Ethical Considerations in 3D Bioprinting?

Despite its promising applications, 3D bioprinting faces several technical, ethical, and regulatory challenges that need to be addressed for it to reach its full potential. One of the primary technical hurdles is the complexity of printing functional tissues that can survive and integrate into the human body. While simpler tissues like skin or cartilage have been successfully bioprinted, more complex organs such as the liver or heart pose significant challenges. These organs require intricate vascular networks to ensure a sufficient blood supply to all areas, and replicating such complex structures remains a major challenge. Moreover, the development of bio-inks that can accurately replicate the diverse mechanical and biological properties of human tissues is an ongoing area of research. Ethically, the ability to print human tissues raises a host of concerns. The potential for creating fully functional human organs could lead to debates over human cloning or the commodification of human tissues. Additionally, there is concern about the equitable distribution of this technology, as it may initially be prohibitively expensive and accessible only to those with the financial means, further exacerbating healthcare inequalities. On the regulatory side, governing bodies are still adapting to the unique challenges posed by bioprinting. Unlike traditional medical devices or pharmaceuticals, bioprinted tissues and organs straddle the line between biological products and synthetic materials, raising questions about how to ensure their safety and efficacy before they can be widely used in clinical settings. Addressing these challenges will be crucial to the widespread adoption and ethical use of 3D bioprinting technology.

What Are the Drivers Behind the Growth of the 3D Bioprinting Market?

The growth in the 3D bioprinting market is driven by several factors, all of which highlight the increasing demand for this revolutionary technology across multiple industries. Technological advancements are playing a critical role in the expansion of the market. Innovations in bioprinting equipment, such as higher resolution printers capable of more intricate designs, and advancements in bio-ink formulations that better mimic human tissues, are continuously pushing the boundaries of what can be achieved. These improvements have opened new possibilities in medical applications, attracting investment from both the public and private sectors. Pharmaceutical companies are also major drivers of growth, using bioprinting to accelerate drug discovery and testing processes. The technology offers a more reliable and cost-effective alternative to traditional methods, which often rely on animal testing that may not translate well to human biology. Additionally, the rise in chronic diseases and conditions associated with aging populations, such as heart disease and liver failure, is driving demand for regenerative medicine solutions, where 3D bioprinting offers patient-specific treatments that can improve outcomes. Another significant factor is the growing consumer preference for personalized medicine. Patients and healthcare providers are increasingly seeking treatments that are tailored to individual genetic profiles, and bioprinting offers the possibility of creating tissues and organs customized to each patient’s unique needs. Finally, the influx of government funding and partnerships with academic institutions has spurred research and development in the field, further accelerating innovation and the commercialization of bioprinting technologies. These trends indicate that 3D bioprinting is poised to become an integral part of the future of healthcare, with wide-ranging applications from organ transplantation to drug development.

SCOPE OF STUDY:

The report analyzes the 3D Bioprinting market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Inkjet-based, Magnetic Levitation, Laser-based, Other Technology); Material (Living Cells, Hydrogels, Extracellular Matrices, Other Materials); End-Use (Research Organizations & Academic Institutes, Biopharmaceutical Companies, Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • 3D Bioprinting Solutions
  • 3D Systems
  • Advanced Solutions Life Sciences
  • Allevi Inc.
  • Aspect Biosystems Ltd.
  • Bio3D Technologies
  • Cellink
  • Cellink Global
  • Cyfuse Biomedical K.K.
  • Digilab, Inc.
  • Envisiontec
  • Gesim
  • Inventia Life Science Pty Ltd.
  • Materialise NV
  • Nano3D Biosciences, Inc.
  • Oceanz 3D printing & Additive Manufacturing
  • Organovo Holdings, Inc.
  • Poietis
  • Regemat 3D S.L.
  • Regenhu
  • Regenovo Biotechnology Co., Ltd.
  • Rokit Healthcare
  • Solidscape
  • Stratasys Ltd.
  • Tevido Biodevices
  • Vivax Bio, LLC
  • Voxeljet

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • 3D Bioprinting - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Tissue Engineering Expands Market Opportunity for 3D Bioprinting
    • Technological Advancements in Bioinks Propel Growth in 3D Bioprinting Applications
    • Increasing Use of 3D Bioprinting in Drug Development and Testing Spurs Market Growth
    • Advances in Stem Cell Research Strengthen the Business Case for 3D Bioprinting in Regenerative Medicine
    • Growing Focus on Organ Transplantation Solutions Accelerates Demand for 3D Bioprinting
    • Here's the Story: Expanding Research in Cancer Therapeutics Drives Innovation in 3D Bioprinting
    • Increasing Application of 3D Bioprinting in Cosmetic Testing and Tissue Models Generates New Opportunities
    • Expanding Use of 3D Bioprinting in the Development of Complex Tissue Structures Strengthens Market Demand
    • Advances in Automation and Robotics Drive Efficiency in 3D Bioprinting Systems
    • Increasing Adoption of 3D Bioprinting in Academic and Research Institutes Expands Market Reach
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Living Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Living Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Hydrogels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Hydrogels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Extracellular Matrices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Extracellular Matrices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Other Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Research Organizations & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Research Organizations & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World 3D Bioprinting Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for 3D Bioprinting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for 3D Bioprinting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Inkjet-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Inkjet-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Magnetic Levitation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Magnetic Levitation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Laser-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Laser-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • JAPAN
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • CHINA
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • EUROPE
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for 3D Bioprinting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for 3D Bioprinting by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • FRANCE
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • GERMANY
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • UNITED KINGDOM
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • ASIA-PACIFIC
    • 3D Bioprinting Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for 3D Bioprinting by End-Use - Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals and Research Organizations & Academic Institutes for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for 3D Bioprinting by Technology - Inkjet-based, Magnetic Levitation, Laser-based and Other Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for 3D Bioprinting by Technology - Percentage Breakdown of Value Sales for Inkjet-based, Magnetic Levitation, Laser-based and Other Technology for the Years 2025 & 2030

IV. COMPETITION